This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Motzer RJ , Jonasch E , Agarwal N , Beard C , Bhayani S , Bolger GB , Chang SS , Choueiri TK , Costello BA , Derweesh IH , Gupta S , Hancock SL , Kim JJ , Kuzel TM , Lam ET , Lau C , Levine EG , Lin DW , Michaelson MD , Olencki T , Pili R , Plimack ER , Rampersaud EN , Redman BG , Ryan CJ , Sheinfeld J , Shuch B , Sircar K , Somer B , Wilder RB , Dwyer M , Kumar R
Kidney cancer, version 3.2015
J Natl Compr Canc Netw. 2015 Feb;13(2) :151-9
AbstractThe NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.
Notes1540-1413 Motzer, Robert J Jonasch, Eric Agarwal, Neeraj Beard, Clair Bhayani, Sam Bolger, Graeme B Chang, Sam S Choueiri, Toni K Costello, Brian A Derweesh, Ithaar H Gupta, Shilpa Hancock, Steven L Kim, Jenny J Kuzel, Timothy M Lam, Elaine T Lau, Clayton Levine, Ellis G Lin, Daniel W Michaelson, M Dror Olencki, Thomas Pili, Roberto Plimack, Elizabeth R Rampersaud, Edward N Redman, Bruce G Ryan, Charles J Sheinfeld, Joel Shuch, Brian Sircar, Kanishka Somer, Brad Wilder, Richard B Dwyer, Mary Kumar, Rashmi Journal Article United States J Natl Compr Canc Netw. 2015 Feb;13(2):151-9.